Vandetanib, a FDA-approved medullary thyroid cancer therapy that inhibits EGFR (22), impairs the HIF-1 pathway by targeting the mTOR–HIF-1α–VEGF signaling axis in breast cancer cells (23) and increases survival in advanced medullary thyroid carcinoma (268). The gene discussed is EGFR; the disease is medullary thyroid gland carcinoma.